

Thrombosis Research Group Core Publications 2023 (by October 15)

1. Meknas D, Braekkan SK, Hansen JB, Morelli VM. Surgery As a Trigger for Incident Venous Thromboembolism: Results from a Population-Based Case-Crossover Study. *TH Open*. 2023; **7**: e244-e50. 10.1055/a-2159-9957.
2. Wahlund CJE, Caglayan S, Czarnewski P, Hansen JB, Snir O. Sustained and intermittent hypoxia differentially modulate primary monocyte immunothrombotic responses to IL-1 β stimulation. *Front Immunol*. 2023; **14**: 1240597. 10.3389/fimmu.2023.1240597.
3. Wikan VE, Tondel BG, Morelli VM, Brodin EE, Braekkan SK, Hansen JB. Diagnostic Blood Biomarkers for Acute Pulmonary Embolism: A Systematic Review. *Diagnostics (Basel)*. 2023; **13**. 10.3390/diagnostics13132301.
4. Leknessund OGR, Morelli VM, Hansen JB, Braekkan SK. Hand grip strength in venous thromboembolism: risk of recurrence and mortality. *Res Pract Thromb Haemost*. 2023; **7**: 102138. 10.1016/j.rpth.2023.102138.
5. Jorgensen CT, Tavoly M, Forsund E, Pettersen HH, Tjonnfjord E, Ghanima W, Braekkan SK. Incidence of bleeding and recurrence in isolated distal deep vein thrombosis: findings from the Venous Thrombosis Registry in Ostfold Hospital. *J Thromb Haemost*. 2023. 10.1016/j.jtha.2023.06.028.
6. Hansen ES, Edvardsen MS, Aukrust P, Ueland T, Hansen JB, Braekkan SK, Morelli VM. Combined effect of high factor VIII levels and high mean platelet volume on the risk of future incident venous thromboembolism. *J Thromb Haemost*. 2023. 10.1016/j.jtha.2023.06.022.
7. Frischmuth T, Tondel BG, Braekkan SK, Hansen JB, Morelli VM. The Risk of Incident Venous Thromboembolism Attributed to Overweight and Obesity: The Tromso Study. *Thromb Haemost*. 2023. 10.1055/s-0043-1772212.
8. Braekkan SK, Hansen JB. VTE epidemiology and challenges for VTE prevention at the population level *Thrombosis Update*. 2023; **10**.
9. Osterud B, Latysheva N, Hansen JB, Snir O. "A rapid, sensitive, and specific assay to measure tissue factor activity based on chromogenic determination of thrombin generation": reply. *J Thromb Haemost*. 2023; **21**: 1062-3. 10.1016/j.jtha.2022.12.025.
10. de Winter MA, Uijl A, Buller HR, Carrier M, Cohen AT, Hansen JB, Kaasjager K, Kakkar AK, Middeldorp S, Raskob GE, Sorensen HT, Wells PS, Nijkeuter M, Dorresteijn JAN. Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis. *J Thromb Haemost*. 2023; **21**: 573-85. 10.1016/j.jtha.2022.11.013.
11. de Winter MA, Buller HR, Carrier M, Cohen AT, Hansen JB, Kaasjager KAH, Kakkar AK, Middeldorp S, Raskob GE, Sorensen HT, Visseren FLJ, Wells PS, Dorresteijn JAN, Nijkeuter M, group V-Ps. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. *Eur Heart J*. 2023; **44**: 1231-44. 10.1093/eurheartj/ehac776.
12. Caglayan S, Hansen JB, Snir O. Optimized workflow to modify microRNA expression in primary human intravascular cells. *BMC Immunol*. 2023; **24**: 5. 10.1186/s12865-023-00540-9.

13. Swamy S, Ueland T, Hansen JB, Snir O, Braekkan SK. Plasma levels of P-selectin and future risk of incident venous thromboembolism. *J Thromb Haemost.* 2023. 10.1016/j.jtha.2023.04.038.
14. Skjeflo EW, Evensen LH, Jensen SB, Latysheva N, Michelsen A, Ueland T, Braekkan SK, Hindberg K, Snir O, Mollnes TE, Hansen JB. Complement factors B, D, C3bBbP and risk of future venous thromboembolism. *Clin Immunol.* 2023; **249**: 109278. 10.1016/j.clim.2023.109278.
15. Rinde FB, Jorgensen CT, Pettersen HH, Hansen JB, Ghanima W, Braekkan SK. Low D-dimer levels at diagnosis of venous thromboembolism are associated with reduced risk of recurrence: data from the TROLL registry. *J Thromb Haemost.* 2023. 10.1016/j.jtha.2023.03.026.
16. Jorgensen H, Horvath-Puho E, Laugesen K, Braekkan SK, Hansen JB, Sorensen HT. Venous thromboembolism and risk of depression: a population-based cohort study. *J Thromb Haemost.* 2023; **21**: 953-62. 10.1016/j.jtha.2022.12.006.
17. Grover SP, Snir O, Hindberg K, Englebert TM, Braekkan SK, Morelli VM, Jensen SB, Wolberg AS, Mollnes TE, Ueland T, Mackman N, Hansen JB. High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism. *J Thromb Haemost.* 2023. 10.1016/j.jtha.2023.03.024.
18. Grover SP, Kawano T, Wan J, Tanratana P, Polai Z, Shim YJ, Snir O, Braekkan S, Dhrolia S, Kasthuri RR, Bendapudi PK, McCrae KR, Wolberg AS, Hansen JB, Farkas H, Mackman N. C1 inhibitor deficiency enhances contact pathway-mediated activation of coagulation and venous thrombosis. *Blood.* 2023; **141**: 2390-401. 10.1182/blood.2022018849.
19. Edvardsen MS, Hansen ES, Ueland T, Aukrust P, Braekkan SK, Morelli VM, Hansen JB. Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism. *J Thromb Haemost.* 2023; **21**: 1227-37. 10.1016/j.jtha.2023.01.024.
20. Crobach MJ, Anijs RJ, Braekkan SK, Severinsen MT, Hammerstrom J, Skille H, Kristensen SR, Paulsen B, Tjonneland A, Versteeg HH, Overvad K, Hansen JB, Naess IA, Cannegieter SC. Survival after Cancer-related Venous Thrombosis: the Scandinavian Thrombosis and Cancer Study. *Blood Adv.* 2023. 10.1182/bloodadvances.2022009577.
21. Farmakis IT, Barco S, Hobohm L, Braekkan SK, Connors JM, Giannakoulas G, Hunt BJ, Keller K, Mavromanoli AC, Trinchero A, Konstantinides SV, Valerio L. Maternal mortality related to pulmonary embolism in the United States, 2003-2020. *Am J Obstet Gynecol MFM.* 2023; **5**: 100754. 10.1016/j.ajogmf.2022.100754.